Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Patent
1992-11-23
1999-01-19
Walsh, Stephen
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
4353201, 536 235, 536 2431, 530350, 935 9, C12N 121, C07H 2104
Patent
active
058613013
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This application is the U.S. National Stage of PCT/US92/01300, filed Feb. 20, 1992 filed under 35 USC .sctn. 371.
This invention relates to the DNA sequence encoding a novel human growth factor receptor which is a type III receptor tyrosine kinase. The receptor is referred to as Kinase insert Domain containing Receptor (KDR) and binds specifically to the growth factor vascular endothelial cell growth factor (VEGF). This invention also relates to the amino acid sequence of the receptor.
BACKGROUND OF THE INVENTION
Growth factors are small molecules which regulate normal cell growth and development through interaction with cell surface receptors. The receptors for a number of growth factors are referred to as tyrosine kinases; that is, binding of growth factor to the receptor stimulates an increased phosphorylation of tyrosine amino acids within the receptor; this is turn leads to cellular activation (Bibliography 1).
There is increasing evidence that genetic alterations affecting the expression of receptor tyrosine kinases (RTK) can contribute to the altered cell growth associated with cancer. This conclusion is supported by the frequent identification of RTK as products of the oncogenes for many of the acutely transforming retroviruses (e.g., 2,3,4) and the overexpression of RTK in certain cancers (5). The identification of a novel RTK may lead to a better understanding of cell growth under both normal and transforming circumstances.
The amino acid sequence in the catalytic domain of all tyrosine kinases has been conserved (6). Detailed analysis of the amino acid sequences within the catalytic and noncatalytic domains of RTK indicates the existence of distinct structural subtypes. One group of RTK (designated type III) includes the ckit proto-oncogene and the receptors for platelet derived growth factor (PDGF) and colony stimulating factor-1 (CSF-1).
The most unusual feature of this subtype is that its catalytic (kinase) domain is interrupted by a long insertion sequence of 12-102 amino acids (the kinase insert domain) The two peptides constituting the kinase domain are conserved between the receptors, while the sequence of the kinase insert domain is unique for each receptor.
Several approaches have been tried in order to identify novel RTK, including low-stringency screening of cDNA libraries with previously characterized DNA probes (7). More recently, a technique has been developed that is capable of greatly facilitating the identification of novel genes for which some sequence data are known. The polymerase chain reaction (PCR) has been used to identify novel members of several gene families including those of guanine nucleotide regulatory proteins (8) and protein phosphatases (9). PCR has been used to identify novel tyrosine kinase genes (10), though the primers used in that study were designed from DNA segments contained in all tyrosine kinases, rather than being specifically directed against RTK. It is a continuing goal to identify receptors for growth factors.
The elucidation of the growth factors, as well as their receptors, involved in regulating endothelial cell function is critical for the understanding of how new blood vessels are formed (angiogenesis). Angiogenesis plays a significant role in both normal and pathological events such as embryogenesis, progression of ocular diseases, and wound healing (11). In particular, angiogenesis is an important process for the growth of tumors (11). Angiogenesis is a complex process involving endothelial cell proliferation, migration, and tissue infiltration. These events are stimulated by growth factors which either (i) act directly on endothelial cells (12,13), or (ii) act indirectly by inducing host cells to release specific endothelial cell growth factors (11). One member of the first group is vascular endothelial cell growth factor (VEGF), also known as vascular permeability factor (14-16). Besides its angiogenic activity, VEGF displays the physiological function of increasing the permeability of capillary vessels to differ
REFERENCES:
patent: 4743679 (1988-05-01), Cohen et al.
patent: 4966841 (1990-10-01), Riley
patent: 5283354 (1994-02-01), Lemischka
R.G.K. Gronwald et al., PNAS 85:34535-3439, May 1988.
J.U. Bowie etal., Science 247:1306, 16 Mar. 1990.
M. Shibuya et al., Oncogene 5:519-524, 1990.
Carrion Miguel Eduardo
Terman Bruce Israel
American Cayanamid Company
Barnhard Elizabeth M.
Gordon Alan M.
Spector L.
Walsh Stephen
LandOfFree
Recombinant kinase insert domain containing receptor and gene en does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant kinase insert domain containing receptor and gene en, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant kinase insert domain containing receptor and gene en will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246119